IMO Kazia management is in-licencing the new drug, because researchers have conducted laboratory combination research with paxalisib and the data synergistically improves the outcome for the patients. A new eureka moment!
A new paxalisib combination trial to be announced.at the same time.
Regards.
- Forums
- ASX - By Stock
- KZA
- Ann: Trading Halt
Ann: Trading Halt, page-34
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)